Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Samrat Pharmachem's EBITDA for the
three
months ended in Mar. 2026 was ₹-16 Mil. Samrat Pharmachem's Revenue for the
three
months ended in Mar. 2026 was ₹718 Mil. Therefore, Samrat Pharmachem's EBITDA margin for the quarter that ended in Mar. 2026 was -2.16%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Samrat Pharmachem EBITDA Margin % Related Terms
Samrat Pharmachem EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Samrat Pharmachem's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem (BOM:530125) has a EBITDA Margin % of -2.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Samrat Pharmachem and its competitors. According to the industry distribution chart, Samrat Pharmachem ranks #1317 out of 1577 companies in the Chemicals industry, placing it in the top 83.5%.
Is Samrat Pharmachem's EBITDA Margin % too high?
Samrat Pharmachem's current EBITDA Margin % is -2.16%. Based on the distribution chart, Samrat Pharmachem ranks #1317 out of 1577 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #1317 out of 1577 companies for EBITDA Margin %. This places Samrat Pharmachem in the lower half of its industry. The industry median EBITDA Margin % is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.65, based on 1,577 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current EBITDA Margin % is -2.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.79, compared to a current price of ₹247.85 — trading 31.7% below its estimated fair value. The current EBITDA Margin % is -2.16%. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current EBITDA Margin % is -2.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹247.85 is trading 31.7% below its estimated GF Value™ of ₹362.79.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
EBITDA Margin %: -2.16%
GF Value™: ₹362.79 vs. price of ₹247.85 (31.7% below fair value)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score
Get the complete analysis for BOM:530125
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
